Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes

Acta Pharmacologica Sinica

Volumn 32, Issue 8, 2011, Pages 999-1008

  Zhou, Hong ^a   Li, Yong Jun ^a   Wang, Mian ^a   Zhang, Li Hui ^a   Guo, Bing Yan ^a   Zhao, Zhan Sheng ^a   Meng, Feng Ling ^a   Deng, Yong Gui ^a   Wang, Rui Ying ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

c Jun NH 2 terminal kinase; diabetes; myocardial fibrosis; Rho kinase; transforming growth factor

Indexed keywords

CHOLESTEROL; FASUDIL; HEMOGLOBIN A1C; MESSENGER RNA; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN C JUN; RECOMBINANT HUMAN INSULIN; RHO KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HEART; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENDOMYOCARDIAL FIBROSIS; FEMALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN;

EID: 80051534873     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.54     Document Type: Article

References (47)

1. Gustafsson I, Hildebrandt P. Early failure of the diabetic heart. Diabetes Care 2001; 24: 3-4. (Pubitemid 32104210)
2. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24: 5-10. (Pubitemid 32104211)
3. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446-56. (Pubitemid 36648590)
4. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-5.
5. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307-10. (Pubitemid 34033407)
6. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238: 31-9. (Pubitemid 41560951)
7. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595-603. (Pubitemid 46455962)
8. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-23.
9. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-96. (Pubitemid 39141972)
10. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin IIinduced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 2005; 512: 215-22. (Pubitemid 40544356)
11. Omura T, Yoshiyama M, Matsumoto R, Kusuyama T, Enomoto S, Nishiya D, et al. Role of c-Jun NH2-terminal kinase in G-proteincoupled receptor agonist-induced cardiac plasminogen activator inhibitor-1 expression. J Mol Cell Cardiol 2005; 38: 583-92. (Pubitemid 40461822)
12. Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008; 153: 1409-19. (Pubitemid 351481520)
13. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 1831-6. (Pubitemid 41243450)
14. Zyadeh FN, Sharma K, Erickson M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose in mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-42. (Pubitemid 24072793)
15. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor β. Cardiovasc Res 2005; 65: 694-701. (Pubitemid 40138990)
16. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313-20. (Pubitemid 41175991)
17. Islam MS, Choi H. Nongenetic model of type 2 diabetes: A comparative study. Pharmacology 2007; 79: 243-9. (Pubitemid 46848544)
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9. (Pubitemid 15018832)
19. Tran TT, Gupta N, Goh T, Naigamwalla D, Chia MC, Koohestani N, et al. Direct measure of insulin sensitivity with the hyperinsulinemiceuglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: Correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev 2003; 12: 47-56. (Pubitemid 36110157)
20. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circ Res 2003; 93: 246-53. (Pubitemid 36993236)
21. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 2004; 95: E45-55.
22. Tanaka S, Hayashi T, Toyoda T, Hamada T, Shimizu Y, Hirata M, et al. High-fat diet impairs the effects of a single bout of endurance exercise on glucose transport and insulin sensitivity in rat skeletal muscle. Metabolism 2007; 56: 1719-28 (Pubitemid 350060940)
23. Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem 2008; 19: 505-13. (Pubitemid 351952320)
24. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocintreated rat. Metabolism 2000; 49: 1390-4.
25. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202. (Pubitemid 36068707)
26. Vadlamudi RV, Rodgers RL, McNeill JH. The effect of chronic alloxanand streptozotocin-induced diabetes on isolated rat heart performance. Can J Physiol Pharm 1982; 60: 902-11. (Pubitemid 12050005)
27. Norby FL, Aberle NS, Kajstura J, Anversa P, Ren J. Transgenic overexpression of insulin-like growth factor I prevents streptozotocininduced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes. J Endocrinol 2004; 180: 175-82. (Pubitemid 38180769)
28. Ren J, Duan J, Thomas DP, Yang X, Sreejayan N, Sowers JR, et al. IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol 2008; 294: R793-802. (Pubitemid 351346955)
29. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008; 149: 380-8.
30. Jin D, Takai S, Sugiyama T, Hayashi T, Fukumoto M, Oku H, et al. Longterm angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. J Pharmacol Sci 2009; 109: 275-84.
31. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82. (Pubitemid 34615941)
32. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005; 28: 483-90. (Pubitemid 41195386)
33. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251-7. (Pubitemid 41429255)
34. Fukushima M, Nakamuta M, Kohjima M, Kotoh K, Enjoji M, Kobayashi N, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int 2005; 25: 829-38. (Pubitemid 41038664)
35. Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH, et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 2007; 75: 51-8. (Pubitemid 46873512)
36. Soliman H, Craig GP, Nagareddy P, Yuen VG, Lin G, Kumar U, et al. Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res 2008; 79: 322-30. (Pubitemid 351951610)
37. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002; 55: 757-67.
38. Chen X, Tian Y, Yao L, Zhang J, Liu Y. Hypoxia stimulates proliferation of rat neural stem cells with influence on the expression of cyclin D1 and c-Jun N-terminal protein kinase signaling pathway in vitro. Neuroscience 2010; 165: 705-14.
39. Zhou CH, Wu XH, Wu YQ. Nobiletin, a dietary phytochemical, inhibits vascular smooth muscle cells proliferation via calcium-mediated c-Jun N-terminal kinases pathway. Eur J Pharmacol 2009; 615: 55-60.
40. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCKJNK signaling axis. Mol Cell 2004; 14: 29-41. (Pubitemid 38469907)
41. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008; 294: H1804-14. (Pubitemid 351490610)
42. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-201. (Pubitemid 44141909)
43. Lee DH, Shi J, Jeoung NH, Kim MS, Zabolotny JM, Lee SW, et al. Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem 2009; 284: 11776-80.
44. Han MJ, Kim BY, Yoon SO, Chung AS. Cell proliferation induced by reactive oxygen species is mediated via mitogen-activated protein kinase in Chinese hamster lung fibroblast (V79) cells. Mol Cells 2003; 15: 94-101.
45. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005; 111: 2741-7. (Pubitemid 40791544)
46. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105: 1545-7. (Pubitemid 34297629)
47. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study. J Cardiovasc Pharmacol 2002; 40: 751-61. (Pubitemid 36109293)